Dashboard
1
Poor Management Efficiency with a low ROCE of 2.44%
- The company has been able to generate a Return on Capital Employed (avg) of 2.44% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 3.59% and Operating profit at -209.56% over the last 5 years
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,036 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.07
-5.07%
3.76
Revenue and Profits:
Net Sales:
63 Million
(Quarterly Results - Jun 2026)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.65%
0%
-0.65%
6 Months
-22.98%
0%
-22.98%
1 Year
-22.91%
0%
-22.91%
2 Years
66.06%
0%
66.06%
3 Years
4.93%
0%
4.93%
4 Years
18.22%
0%
18.22%
5 Years
6.03%
0%
6.03%
Tus-Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.59%
EBIT Growth (5y)
-209.56%
EBIT to Interest (avg)
-8.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0.47
Tax Ratio
1.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.20%
ROE (avg)
2.40%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.72
EV to EBIT
-54.96
EV to EBITDA
-179.44
EV to Capital Employed
3.91
EV to Sales
5.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-7.11%
ROE (Latest)
-5.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
62.50
77.20
-19.04%
Operating Profit (PBDIT) excl Other Income
-0.50
4.40
-111.36%
Interest
0.40
1.00
-60.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.20
-1.00
-720.00%
Operating Profit Margin (Excl OI)
-137.60%
-52.50%
-8.51%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -19.04% vs 10.92% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -720.00% vs 93.33% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
335.10
340.70
-1.64%
Operating Profit (PBDIT) excl Other Income
1.00
-23.10
104.33%
Interest
3.50
3.70
-5.41%
Exceptional Items
-26.40
-119.60
77.93%
Consolidate Net Profit
-50.10
-127.20
60.61%
Operating Profit Margin (Excl OI)
-95.10%
-153.60%
5.85%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -1.64% vs -15.06% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 60.61% vs -610.84% in Dec 2024
About Tus-Pharmaceutical Group Co., Ltd. 
Tus-Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






